Abrupt
发表于 2025-3-28 16:24:16
http://reply.papertrans.cn/47/4625/462446/462446_41.png
彩色
发表于 2025-3-28 21:13:07
Kaoru Nakata,Hiroya Sugisakicans. These techniques will establish BMD at a particular time. Using serial DXA measurements it is possible to measure a change in BMD over a set period of time. It is presumed that these measured changes in BMD are caused by alterations in bone turnover, but they are not direct measurements of bon
无目标
发表于 2025-3-28 23:03:40
thritis‘ is aimed at principal investigators pharmaceutical physicians and other pharmaceutical staff involved in the design, conduct and monitoring of these increasingly complex diseases... ..In the last several years a new classes of biologic agents have emerged and changed the treatment paradigm
parsimony
发表于 2025-3-29 05:05:48
Hideki Kaeriyama Trials in Rheumatoid Arthritis and Osteoarthritis‘ is aimed at principal investigators pharmaceutical physicians and other pharmaceutical staff involved in the design, conduct and monitoring of these increasingly complex diseases... ..In the last several years a new classes of biologic agents have
改正
发表于 2025-3-29 07:44:17
Hideki Kaeriyama Trials in Rheumatoid Arthritis and Osteoarthritis‘ is aimed at principal investigators pharmaceutical physicians and other pharmaceutical staff involved in the design, conduct and monitoring of these increasingly complex diseases... ..In the last several years a new classes of biologic agents have
Generic-Drug
发表于 2025-3-29 15:08:11
http://reply.papertrans.cn/47/4625/462446/462446_46.png
名次后缀
发表于 2025-3-29 15:46:55
Daisuke Ambe,Hideki Kaeriyama,Yuya Shigenobu,Ken Fujimoto,Tsuneo Ono,Hideki Sawada,Hajime Saito,Miki Trials in Rheumatoid Arthritis and Osteoarthritis‘ is aimed at principal investigators pharmaceutical physicians and other pharmaceutical staff involved in the design, conduct and monitoring of these increasingly complex diseases... ..In the last several years a new classes of biologic agents have
euphoria
发表于 2025-3-29 21:04:07
Tsuneo Ono,Daisuke Ambe,Hideki Kaeriyama,Yuya Shigenobu,Ken Fujimoto,Kiyoshi Sogame,Nobuya Nishiura, Trials in Rheumatoid Arthritis and Osteoarthritis‘ is aimed at principal investigators pharmaceutical physicians and other pharmaceutical staff involved in the design, conduct and monitoring of these increasingly complex diseases... ..In the last several years a new classes of biologic agents have
multiply
发表于 2025-3-30 00:56:17
http://reply.papertrans.cn/47/4625/462446/462446_49.png
金哥占卜者
发表于 2025-3-30 04:43:24
http://reply.papertrans.cn/47/4625/462446/462446_50.png